From 2018 chemistry development and clinical manufacturing capabilities has moved to the Chemical Division under the API development and manufacturing business unit.
In 2017 Lonza launched XS™ Pichia 2.0, an expression and manufacturing platform for development of next-generation therapeutics. The reporting year also saw Lonza execute our first plasmid DNA project.
Our Drug Product Services team in Basel (CH) expanded in 2017 and now has 45 experts working on innovative solutions in parenteral formulations and dosage forms. We have filed several patents based on significant scientific output.
Capsugel's drug formulation team and Lonza's DPS team now form a strong basis for our growing formulation services in small and large molecules.
The Mammalian team launched new service offerings for support of early-phase biopharmaceutical drug development. These services included Protein Sequence Variant Analysis (PSVA), Developability Assessment for microbial-derived products, and new cell-line construction options including Multiplex CLC. Site expansion in Slough included additional single-use bioreactors. Lonza's new California site in Hayward is for clinical manufacture based on single-use technology.
We continued to invest in automation to improve project throughput and product quality from cell-line construction through process development. Also we expanded the pipeline of early-phase small molecules from both large and small biotech companies.